REMARKS OF DR. J. ALLAN WA1TZ TO THE RECOMBINANT DNA ADVISORY 
COMMITTEE'S LARGE SCALE REVIEW WORKING GROUP, OCTOBER 26, 1982. 
Good morning Ladies and Gentlemen: 
My name is Allan Waitz. I was, until recently, Vice President, 
Microbiological Research, Schering-Plough Corporation and am now 
President and Chief Operating Officer of DNAX Research Institute 
of Molecular and Cellular Biology, a wholly owned subsidiary of 
Schering-Plough Corporation. 
I want to thank you for this opportunity to share with you 
Schering's suggestions for changes in the NIH Guidelines for 
Research Involving Recombinant DNA Molecules and also the 
Large-Scale Physical Containment Recommendations. As you know, 
our industry has not always been supportive of the regulatory 
direction taken in the early years of this new technology. Over 
the more recent years, however, we have observed the development 
of these guidelines and have grown increasingly confident that 
they reflect prudent practices and controls. 
As a multinational corporation doing business throughout the 
world, Schering has voluntarily adopted these guidelines in our 
domestic plants in Omaha, Nebraska and Bloomfield and Union, NJ 
as well as in our overseas plant in Ireland, where we have made a 
commitment to the Irish government that any production in that 
country utilizing recombinant DNA technology will be conducted in 
accordance with the NIH guidelines. Schering is committed to 
October 1, 1982 
[593] 
